Last 132.00 GBp
Change Today -2.00 / -1.49%
Volume 75.3K
VEC On Other Exchanges
Symbol
Exchange
London
OTC US
Frankfurt
As of 5:04 AM 11/26/14 All times are local (Market data is delayed by at least 15 minutes).

vectura group plc (VEC) Snapshot

Open
132.25 GBp
Previous Close
134.00 GBp
Day High
134.00 GBp
Day Low
132.00 GBp
52 Week High
02/19/14 - 171.50 GBp
52 Week Low
11/26/13 - 103.00 GBp
Market Cap
531.3M
Average Volume 10 Days
1.9M
EPS TTM
-0.02 GBp
Shares Outstanding
402.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VECTURA GROUP PLC (VEC)

Related News

No related news articles were found.

vectura group plc (VEC) Related Businessweek News

No Related Businessweek News Found

vectura group plc (VEC) Details

Vectura Group plc researches, develops, and commercialises novel therapeutic products and drug delivery systems for the treatment of airways-related diseases. The company offers ADVATE for the treatment of haemophilia A; Adept for the treatment of surgical adhesions; Extraneal for the treatment of peritoneal dialysis; Seebri Breezhaler and Ultibro Breezhaler for the treatment of chronic obstructive pulmonary disease (COPD); and AirFlusal Forspiro for the treatment of asthma and COPD, as well as Asmasal and Asmabec for the treatment of asthma. Its full development stage products include VR315, VR506, and VR632 for the treatment of asthma. The company’s Phase III clinical stage products include NVA237 and QVA149 for the treatment of COPD; VR475 for the treatment severe adult asthma; and VR876 for the treatment of pulmonary hypertension. Its Phase II clinical stage products comprise VR647 for the treatment of paediatric asthma; VR179 for the treatment of cystic fibrosis; VR736 for the treatment severe influenza; and SB010 for the treatment of asthma and other respiratory diseases. The company’s Phase I clinical stage products include VR475 for the treatment severe adult asthma; VR465 for the treatment for respiratory syncytial virus infection. Its pre-clinical stage products include VR588 and VR942 for the treatment of inflammatory airway diseases; and VR611 for the treatment of airways inflammatory and chronic cough diseases. The company also provides drug delivery technology platforms, such as PowderHale, a dry powder inhalation (DPI) formulation technology that is designed to enhance the performance of DPI products; PowderMax technology that applies PowderHale approach to spectrum of drug substances; and ParticleMax technology to create a new generation of formulations. In addition, it provides Gryohaler, lever-operated, open-inhale-close, AKITA Jet, APIXNEB, and FOX devices. The company was founded in 1997 and is headquartered in Chippenham, the United Kingdom.

281 Employees
Last Reported Date: 07/30/14
Founded in 1997

vectura group plc (VEC) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 674.0K GBP
Chief Financial Officer, Secretary and Direct...
Total Annual Compensation: 300.0K GBP
Chief Operations Officer, Director and Presid...
Total Annual Compensation: 482.0K GBP
Compensation as of Fiscal Year 2014.

vectura group plc (VEC) Key Developments

Vectura Group plc Announces Czech and Irish Approval for AirFluSal Forspiro

Vectura Group plc confirmed that partner, Sandoz, has been granted marketing authorisation by the regulatory authorities in Ireland and the Czech Republic for AirFluSal®Forspiro®, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD). The receipt of the Czech Republic marketing authorisation by Sandoz triggers a milestone payment to Vectura of €1.5 million. AirFluSal® Forspiro® offers the proven combination of salmeterol (a long-acting inhaled ß2-agonist) and fluticasone propionate (an inhaled corticosteroid) in an innovative new device. The product's safety, efficacy and equivalence have been proven in multiple clinical trials.

Vectura Group plc Announces Executive Changes, Effective from January 1, 2015

Vectura Group plc announced that Andrew J. Oakley, former Chief Financial Officer of Actelion Pharmaceuticals Ltd. will succeed Paul Oliver as CFO, Executive Director, and Company Secretary effective from January 1, 2015. Prior to joining Vectura, Andrew gained considerable experience at two Swiss bio-pharmaceutical companies, including nearly 11 years at Actelion.

Vectura Group plc Reports Unaudited Consolidated Earnings Results for the Six Months Ended Sep. 30, 2014

Vectura Group plc reported unaudited consolidated earnings results for the six months ended Sep. 30, 2014. For the period, the company reported revenue was £19.4 million compared to £17.0 million a year ago. Operating loss was £7.1 million compared to £1.9 million a year ago. Loss before tax was £7.1 million compared to £1.2 million a year ago. Loss after taxation attributable to equity holders of the company was £4.5 million or 1.1 pence basic and diluted per share compared to £0.3 million or 0.1 pence basic and diluted per share a year ago. EBITA was £3.0 million compared to £2.3 million a year ago. Adjusted diluted earnings per ordinary share were 0.7 pence compared to 0.7 pence a year ago. Net cash inflow from operating activities was £2.0 million compared to net cash outflow from operating activities of £7.0 million a year ago. Purchase of property, plant and equipment was £0.6 million compared to £1.3 million a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VEC:LN 132.00 GBp -2.00

VEC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Skyepharma PLC 337.00 GBp 0.00
View Industry Companies
 

Industry Analysis

VEC

Industry Average

Valuation VEC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 13.3x
Price/Book 2.4x
Price/Cash Flow 82.6x
TEV/Sales 13.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VECTURA GROUP PLC, please visit www.vectura.co.uk. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.